Cite
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.
MLA
Wei, Xiao-Li, et al. “Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.” Oncologist, vol. 28, no. 1, Jan. 2023, pp. e36–44. EBSCOhost, https://doi.org/10.1093/oncolo/oyac225.
APA
Wei, X.-L., Zhang, Y., Zhao, H.-Y., Fang, W.-F., Luo, H.-Y., Qiu, M.-Z., He, M.-M., Zou, B.-Y., Xie, J., Jin, C.-L., Zhou, X.-F., Wang, F., Wang, F.-H., Li, Y.-H., Wang, Z.-Q., & Xu, R.-H. (2023). Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials. Oncologist, 28(1), e36–e44. https://doi.org/10.1093/oncolo/oyac225
Chicago
Wei, Xiao-Li, Yang Zhang, Hong-Yun Zhao, Wen-Feng Fang, Hui-Yan Luo, Miao-Zhen Qiu, Ming-Ming He, et al. 2023. “Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.” Oncologist 28 (1): e36–44. doi:10.1093/oncolo/oyac225.